Harry Sokol

Thank you so much @h_sokol for the organisation of these 2 amazing days of @GlycanTrigger meeting full of great science and exciting ongoing results 🧫🧪hosted in the charming city of Paris 🇫🇷 #glycotime @i3S_UPorto

👋🏻Hi Paris! Day 1 of the 3rd @GlycanTrigger GA meeting. We started with a warm welcome from our coordinator, Prof @Salome_S_Pinho and our host partner Dr. @h_sokol (@Sorbonne_Univ_), followed by a seminar delivered by Prof. Guy Gorochov on “Gut Microbiota and IgA”. Stay tuned!👀

Wrapping up day 1 of our 3rd @GlycanTrigger GA meeting 🗼A productive day of presentations and discussions. Through project updates, expert talks, and dialogue, we're continuing to push forward our mission to unravel the role of the gut glycome in immune-mediated diseases💡

Check out our recent work with John Rioux and the iGenoMed Consortium! Serum proteomic and metabolomic profiling in #IBD patients initiating vedolizumab identified pro-inflammatory analytes associated with treatment response. onlinelibrary.wiley.com/doi/10.1111/im…

📣 Join us for a great Keystone meeting on "Human #Microbiome: From Models and Mechanism to Medicine" January 19-22, 2026 Deadlines: - Scholarship: Sept 23 - Abstract (Short Talk): Sept 23 - Early Registration: Nov 20 - Poster Abstract: Dec 30 shorturl.at/QgPzj

Fantastic paper and resource published by @segal_eran in @NatureMedicine

Excited to share a milestone published in @NatureMedicine from our decade-long effort to build The Human Phenotype Project, a unique longitudinal cohort with unmatched depth of clinical and multi-omic profiling, enabling truly predictive, personalized medicine. Led together with…

Join us ! Open #Postdoc position in my lab (Paris, France), to work on the Role of the Gut #microbiota in Host Cells Energy Metabolism in Health and #IBD see details here 🔽🔽🔽🔽 euraxess.ec.europa.eu/jobs/361342 please RT

📣The first ever consensus on dietary management of #IBD is out in @JCC_IBD @VaioSvolos, @IBDTAMRegistry, @MirandaLomer, @AaronBancil, @Alice_APD, @Jess_Fitz_APD, @KGerasimidis, @sarbagili, @BonehRotem, @h_sokol, @CatherineWallNZ, @ProfWhelan, @PaedsRH, @EmmaHalmos & colleagues…

AhR - c'est aussi le dada du Prof. @h_sokol un essai avec Faecalibacterium prausnitzii aurait un intérêt énorme pour le covid long @Molbaas la dernière revue sur les syndromes post infectieux de @AlainTrautmann en fait état - j'ai une revue presque achevée avec @MartinSpanoghe

Morocco&France:A study of 302 patients revealed that severe COVID-19 cases were associated with shifts in gut microbiota. Thanks to Dr Harry Sokol’s team for including us in this outstanding collaborative work and many thanks to the Balvi team for their generous financial support

Happy to share our Perspective "Microbiome for clinicians" authors.elsevier.com/sd/article/S00…, just out in @CellCellPress. A piece written by #microbiomeclinicians (@Siew_C_Ng @GiovanniCammar9 @h_sokol @EranElinav @Elinav_Lab @WeersmaLab & many others) for #microbiome clinicians.

What an absolute honour and privilege to host Prof. Harry Sokol @h_sokol at the University of Calgary as part of the @SnyderInstitute endowed chair series . A packed auditorium listening to a masterful talk on the gut microbiota and IBD. Harry is trailblazing the field .

The gut microbiome has a lot to say in #IBD @h_sokol updates tryptophan, aryl-hydrocarbons and the microbiome potential role on IBD pathways #DDW2025 @DDWMeeting

The future of #IBD therapy is #MICROBIOME @h_sokol #ACG2025

Is the gut microbiota an actor in IBD pathogenesis? YES, and translation to the clinic is on the way Complete masterclass by @h_sokol #DDW2025 Modify gut microbiota impacts disease severity • In mice models • In humans (FMT) Faecal microbiota from patients with IBD…

Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1 | ⁦@Nature⁩ nature.com/articles/s4158…

Global evolution of inflammatory bowel disease across epidemiologic stages | ⁦@Nature⁩ ⁦⁦@gilkaplan⁩ nature.com/articles/s4158…

Dr. Harry Sokol, an expert in gut microbiota and IBD, will present a seminar on “Gut Microbiome in IBD: From Description to Therapeutic Intervention”. events.ucalgary.ca/snyder/event/4… #GutMicrobiome #IBD #SnyderInstitute #MedicalResearch #SeminarSeries #MicrobiomeScience #FreeEvent

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…